News
About Kymera Therapeutics Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and ...
Codexis Announces Six Presentations Featuring the ECO Synthesis Platform at TIDES USA Annual Meeting
In addition, three leading contract development and manufacturing organizations (CDMOs) are presenting data on the performance of Codexis’ double-stranded RNA ligases to combine short RNA fragments, ...
We manufacture all our biosimilars in Iceland, a country which imports more goods from the U.S. than it exports to the U.S., and is therefore only subject to the minimum 10% tariff introduced in April ...
Innovative antisense therapy blocking production of TGF-β2 shows promise in reducing retinal fibrosis and improving outcomes in patients with wet AMD and DME ...
The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
DUBLIN, May 07, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its financial ...
On March 18, 2025, Rhythm announced a new research collaboration with the Raymond A. Wood Foundation, a patient advocacy organization for survivors of craniopharyngioma and hypothalamic-pituitary ...
The Company continues its ongoing partnerships with IMPACT Melanoma, AIM at Melanoma and Melanoma Research Foundation to drive education and awareness throughout May ...
Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher ...
Valneva retransmettra aujourd’hui en direct la conférence téléphonique sur ses résultats financiers du premier trimestre 2025 à 15h00 CEST (9h00 EDT). Cette retransmission sera disponible sur le site ...
CROSSJECT et son partenaire EUROFINS ont achevé avec succès le remplissage aseptique de tous les lots d'enregistrement de ZEPIZURE® et prévoient la livraison des dernières données de fabrication néces ...
Within R&D, Novo Nordisk completed the REDEFINE 2 trial, where CagriSema demonstrated superior weight loss of 15.7% in adults with obesity or overweight and type 2 diabetes. Novo Nordisk still expects ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback